Trending...
- Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
- Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
- AI Is Making It Easier for API-First Platforms to Connect, Partner, Reach Customers, and Grow Revenue Faster
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Details for the virtual fireside chat are as follows:
Date: Tuesday, February 28, 2023
Time: 2:00 PM ET
The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on February 28, 2023: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
More on ncarol.com
- Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
- Equity Shift Holdings Completes Strategic Asset Acquisition with SteadyTrail Technologies
- Go-Forth Home Services Climbs to #33 on 2026 PCT Top 100, Posting 30% Revenue Growth
- Appliance EMT Launches June "Summer Rescue" Promotion
- New Luxury Single Family Homes From $976,990 in Manalapan
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple ex vivo "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Contacts
Investor Contact:
Mei Burris
Director, Investor Relations & Finance
Mei.burris@precisionbiosciences.com
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally
- Looking for expert pool tiling in Gold Coast? Call Avid Tiling
- Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision
- Healthy by Nature® Launches ZeoForce™, a Smarter Alternative to Detox Stacks
- Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
- PropAccount.com Launches PropGenie, the First Branding Studio Built for Prop Firm Operators
- New from Regal House Publishing, Never Leave Me Alone, a race to find who's behind a deadly game
- Rushing Headlong: Health IT's Legacy and the Road to Responsible AI is named 2025 Foreword INDIES Book of the Year Awards Winner
- The Problem With AI Isn't Compute. It's Memory
- Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds
- Allstream Energy Partners Announced as Official Media Partner for the 2nd Annual Permian Power Conference
- Children's Book for Kids with Limb Differences Coming Soon!
- CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
- Boston Industrial Solutions Introduces New Natron® 310 Hyper White UV Ink for Enhanced Printing Performance
- New analysis reveals second job workers keep just 80p in every pound they earn
- NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
- Asheville Clinician Publishes New Hypothesis on Trigeminal Neuralgia in Elsevier Journal
- A Foundational Claim in Human Secrecy Goes Public
- Kappa Foundation of Charlotte Launches Transformational Community Investment Project
- Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States